These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25267972)

  • 21. Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism.
    Boehrer S; Schroeder P; Mueller T; Atz J; Chow KU
    Anticancer Drugs; 2011 Jul; 22(6):519-30. PubMed ID: 21637160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
    Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia.
    Scrivener S; Goddard RV; Kaminski ER; Prentice AG
    Leuk Lymphoma; 2003 Mar; 44(3):383-9. PubMed ID: 12688308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway.
    Porakishvili N; Kardava L; Jewell AP; Yong K; Glennie MJ; Akbar A; Lydyard PM
    Haematologica; 2004 Apr; 89(4):435-43. PubMed ID: 15075077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL.
    Duell J; Dittrich M; Bedke T; Mueller T; Eisele F; Rosenwald A; Rasche L; Hartmann E; Dandekar T; Einsele H; Topp MS
    Leukemia; 2017 Oct; 31(10):2181-2190. PubMed ID: 28119525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
    Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype.
    Göthert JR; Eisele L; Klein-Hitpass L; Weber S; Zesewitz ML; Sellmann L; Röth A; Pircher H; Dührsen U; Dürig J
    Cancer Immunol Immunother; 2013 Nov; 62(11):1697-1709. PubMed ID: 24022692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.
    Klinger M; Benjamin J; Kischel R; Stienen S; Zugmaier G
    Immunol Rev; 2016 Mar; 270(1):193-208. PubMed ID: 26864113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD34+ cord blood DC-induced antitumor lymphoid cells have efficacy in a murine xenograft model of human ALL.
    Cullup H; Hsu AK; Kassianos AJ; McDonald K; Radford KJ; Rice AM
    J Immunother; 2011 May; 34(4):362-71. PubMed ID: 21499125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
    Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
    Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
    Csóka M; Strauss G; Debatin KM; Moldenhauer G
    Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response.
    Hus I; Schmitt M; Tabarkiewicz J; Radej S; Wojas K; Bojarska-Junak A; Schmitt A; Giannopoulos K; Dmoszyńska A; Roliński J
    Leukemia; 2008 May; 22(5):1007-17. PubMed ID: 18323802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenovirus-specific T-cell Subsets in Human Peripheral Blood and After IFN-γ Immunomagnetic Selection.
    Qian C; Wang Y; Cai H; Laroye C; De Carvalho Bittencourt M; Clement L; Stoltz JF; Decot V; Reppel L; Bensoussan D
    J Immunother; 2016 Jan; 39(1):27-35. PubMed ID: 26641259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells.
    Yang R; Shen S; Gong C; Wang X; Luo F; Luo F; Lei Y; Wang Z; Xu S; Ni Q; Xue Y; Fu Z; Zeng L; Fang L; Yan Y; Zhang J; Gan L; Yi J; Zhou P
    Front Immunol; 2021; 12():654080. PubMed ID: 34040604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
    Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
    Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy.
    Zimmerman Z; Maniar T; Nagorsen D
    Int Immunol; 2015 Jan; 27(1):31-7. PubMed ID: 25239133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
    Demanet C; Brissinck J; Leo O; Moser M; Thielemans K
    Cancer Res; 1994 Jun; 54(11):2973-8. PubMed ID: 8187084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.